{"filings":[{"id":2132758,"accession_number":"0001493152-26-036557","cik":719135,"company_name":"Apyx Medical Corp","ticker":"APYX","form_type":"8-K","filed_at":"2026-08-07T20:00:19+00:00","items":["5.02","5.07","9.01"],"status":"ready","headline":"Apyx shareholders approve 2026 Share Incentive Plan with 4M shares","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Stockholders approved 2026 Share Incentive Plan; 16,186,776 for, 2,755,882 against, 3,276,000 abstain, 7,677,267 broker non-votes.","Plan authorizes 4,000,000 shares for options and restricted stock to employees, directors, and consultants.","Five directors elected: Vizirgianakis, Goodwin, Waldman, Baylor-Henry, Levine; all received majority votes.","Say-on-pay advisory resolution approved: 21,458,554 for, 669,298 against, 90,806 abstain.","RSM US LLP ratified as independent auditor for FY2026: 29,814,618 for, 31,610 against, 49,697 abstain."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.4,"calibrated_materiality_score":0.4,"market_cap_usd":171683203.41025642,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":2105983,"accession_number":"0001437749-26-026262","cik":719135,"company_name":"Apyx Medical Corp","ticker":"APYX","form_type":"8-K","filed_at":"2026-08-06T20:09:28+00:00","items":["2.02","9.01"],"status":"ready","headline":"Apyx Medical Q2 revenue $13.9M (+22% YoY); Surgical Aesthetics up 28%; reaffirms FY guidance","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Total revenue $13.9M vs $11.4M in Q2 2025; Surgical Aesthetics segment grew 28% to $12.4M.","Net loss narrowed to $3.2M ($0.07/sh) from $3.8M ($0.09/sh); Adjusted EBITDA loss improved to $0.7M from $2.0M.","Reaffirmed FY2026 revenue guidance $59.0M-$60.0M; Surgical Aesthetics expected $54.0M-$55.0M.","Limited commercial launch of power liposuction handpiece for AYON platform began in June 2026 after FDA clearance.","Cash and equivalents $27.6M; management expects to yield cash through 2027."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":171683203.41025642,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":1859277,"accession_number":"0001493152-26-034619","cik":719135,"company_name":"Apyx Medical Corp","ticker":"APYX","form_type":"8-K","filed_at":"2026-07-24T21:18:18+00:00","items":["8.01","9.01"],"status":"ready","headline":"Apyx Medical reconstitutes board committees; Executive Chairman Vizirgianakis steps off all committees","summary_kind":"llm","event_type":"other","confidence":"high","bullets":["Audit Committee: Lawrence J. Waldman (Chair), Minnie Baylor-Henry, Wendy Levine.","Governance & Nominating: Baylor-Henry (Chair), Waldman, Levine; Regulatory Compliance: Baylor-Henry (Chair), Waldman, Levine; Compensation: Levine (Chair), Waldman, Baylor-Henry.","Stavros Vizirgianakis, appointed Executive Chairman June 11, 2026, will not serve on any committee.","Board determined all three members independent; Waldman qualifies as audit committee financial expert."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.2,"calibrated_materiality_score":0.2,"market_cap_usd":171683203.41025642,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":1111051,"accession_number":"0001493152-26-029081","cik":719135,"company_name":"Apyx Medical Corp","ticker":"APYX","form_type":"8-K","filed_at":"2026-06-17T20:05:19+00:00","items":["1.01","9.01"],"status":"ready","headline":"Apyx Medical appoints Chairman Stavros Vizirgianakis as Executive Chairman; grants 450,000 RSUs","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Stavros Vizirgianakis appointed Executive Chairman effective June 11, 2026; will lead strategic initiatives and investor engagement.","Receives 450,000 RSUs: 150,000 vest immediately, 150,000 over 12 months starting year 1, 150,000 over 12 months starting year 2.","No cash compensation for the role; only expense reimbursement.","Unvested RSUs fully accelerate upon a Change of Control.","Vizirgianakis will not be an officer or employee, nor designated as an executive officer."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":171683203.41025642,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":582476,"accession_number":"0001437749-26-018098","cik":719135,"company_name":"Apyx Medical Corp","ticker":"APYX","form_type":"8-K","filed_at":"2026-05-21T20:23:32+00:00","items":["8.01","9.01"],"status":"ready","headline":"Apyx Medical publishes clinical data showing 81.8% cellulite improvement with Avéli-Renuvion combination","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["22 patients received single-session treatment combining Avéli subcision and Renuvion helium plasma RF.","Up to 81.8% of patients showed improvement in cellulite appearance at 180 days post-treatment.","3D imaging confirmed measurable reductions in dimple volume, surface area, and depth.","Histological analysis in a subset showed increased collagen and elastin with progressive tissue remodeling.","Study published in Aesthetic Surgery Journal Open Forum; supports combined approach for cellulite and skin laxity."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.3,"calibrated_materiality_score":0.3,"market_cap_usd":171683203.41025642,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":77963,"accession_number":"0001437749-26-016885","cik":719135,"company_name":"Apyx Medical Corp","ticker":"APYX","form_type":"8-K","filed_at":"2026-05-14T12:05:35+00:00","items":["8.01","9.01"],"status":"ready","headline":"Renuvion + liposuction shows higher satisfaction, lower revision rates in 113-patient study","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Patients with Renuvion reported higher satisfaction with excess skin: Body-Q score 87.8 vs 73.8 (p=0.03).","Abdominoplasty rate more than 50% lower in Renuvion group (30.0% vs 67.1%).","Revision rate significantly lower with Renuvion (12.0% vs 37.5%; p=0.038).","Complication rates similar between groups (2.5% vs 2.7%).","Study published in Plastic and Reconstructive Surgery - Global Open."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.45,"calibrated_materiality_score":0.45,"market_cap_usd":171683203.41025642,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":98475,"accession_number":"0001437749-26-016000","cik":719135,"company_name":"Apyx Medical Corp","ticker":"APYX","form_type":"8-K","filed_at":"2026-05-11T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Apyx Medical receives FDA clearance for power liposuction on AYON Body Contouring System","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["Expanded FDA 510(k) clearance for AYON Body Contouring System to include power liposuction, a reciprocating cannula for efficient fat removal.","Power liposuction reduces surgeon effort and OR time; adds as second advanced liposuction modality on unified platform.","Company plans limited commercial launch with early adopters to refine training and customer experience before scaling.","CEO Charlie Goodwin says AYON becomes gold-standard system in surgical aesthetics with this clearance."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":171683203.41025642,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":98474,"accession_number":"0001437749-26-015352","cik":719135,"company_name":"Apyx Medical Corp","ticker":"APYX","form_type":"8-K","filed_at":"2026-05-07T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Apyx Medical Q1 revenue $12.5M (+32% YoY); raises FY2026 guidance","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Total revenue $12.5M, up 32% YoY; Surgical Aesthetics grew 36% to $10.7M.","Net loss narrowed to $2.1M ($0.05 loss per share) from $4.2M ($0.10 loss).","Adjusted EBITDA loss improved to $0.3M from $2.4M in prior year.","Raised FY2026 revenue guidance to $59M-$60M from prior $57.5M-$58.5M.","International sales strong, especially South Korea; Renuvion won NewBeauty award."],"consensus_eps_estimate":-0.1081,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":12490000.0,"consensus_period":"2026-Q1","consensus_source":"xbrl+finnhub","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":171683203.41025642,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":113968,"accession_number":"0001437749-26-007420","cik":719135,"company_name":"Apyx Medical Corp","ticker":"APYX","form_type":"8-K","filed_at":"2026-03-10T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Apyx Medical Q4 revenue record $19.2M, net loss narrows; FY2026 guidance $57.5-58.5M","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q4 total revenue record $19.2M, +34.7% YoY; Surgical Aesthetics +38.1% to $16.7M driven by AYON launch.","Q4 net loss narrowed to $1.3M ($0.03/sh) from $4.6M ($0.12/sh); Adjusted EBITDA $0.7M vs ($2.2M).","FY2025 total revenue $52.8M (+9.9% YoY); net loss $11.2M ($0.27/sh) vs $23.5M ($0.66/sh) in 2024.","FY2026 guidance: total revenue $57.5M-$58.5M; Surgical Aesthetics rev $53M-$54M; OEM rev ~$4.5M.","Submitted 510(k) for AYON power liposuction label expansion; clearance anticipated mid-2026."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":171683203.41025642,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":113967,"accession_number":"0001437749-26-001048","cik":719135,"company_name":"Apyx Medical Corp","ticker":"APYX","form_type":"8-K","filed_at":"2026-01-12T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Apyx Medical reports preliminary Q4 revenue up ~34% YoY; Surgical Aesthetics up 38%","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Total Q4 revenue expected $19.0-19.2M, up ~34% YoY; FY revenue $52.7-52.9M, up ~10%.","Surgical Aesthetics Q4 revenue $16.6-16.8M (+38% YoY); U.S. Surgical Aesthetics up ~51% on AYON launch.","OEM Q4 revenue $2.4M (+13% YoY); FY OEM revenue $7.5M (-21% YoY).","CEO cites AYON momentum and GLP-1-driven demand for loose skin procedures.","Full financial results to be reported in March 2026."],"consensus_eps_estimate":-0.0584,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":52844000.0,"consensus_period":"2025-FY","consensus_source":"xbrl+finnhub","sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":171683203.41025642,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":130378,"accession_number":"0001493152-25-027481","cik":719135,"company_name":"Apyx Medical Corp","ticker":"APYX","form_type":"8-K","filed_at":"2025-12-12T23:59:59+00:00","items":["5.03","9.01"],"status":"ready","headline":"Apyx Medical files Certificate of Amendment to delete Article EIGHTH from charter","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Stockholders approved the amendment at the August 7, 2025 annual meeting.","Certificate filed with Delaware Secretary of State on December 8, 2025.","Article EIGHTH replaced with 'intentionally omitted' — no substantive change to business.","Full terms of amendment incorporated by reference from June 25, 2025 proxy statement."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.0,"calibrated_materiality_score":0.0,"market_cap_usd":171683203.41025642,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":130377,"accession_number":"0001493152-25-024279","cik":719135,"company_name":"Apyx Medical Corp","ticker":"APYX","form_type":"8-K","filed_at":"2025-11-19T23:59:59+00:00","items":["1.01","8.01","9.01"],"status":"ready","headline":"Apyx Medical prices $10M public offering of 2.76M shares at $3.62/share","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Offering of 2,762,431 shares priced at $3.62 per share, with gross proceeds ~$9.4M.","Underwriter granted 45-day option for up to 414,365 additional shares.","Lucid Capital Markets is sole book-runner; offering closed Nov 19, 2025.","Net proceeds for working capital, sales/marketing, capex, acquisitions, debt repayment.","Shares issued under effective S-3 shelf registration (File No. 333-268532)."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":171683203.41025642,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":130376,"accession_number":"0001437749-25-033456","cik":719135,"company_name":"Apyx Medical Corp","ticker":"APYX","form_type":"8-K","filed_at":"2025-11-06T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Apyx Medical Q3 rev $12.9M (+12% YoY); net loss $2.0M; raises FY guidance to $50.5-52.5M","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Total revenue $12.9M (+12% YoY); Surgical Aesthetics $11.1M (+19% YoY).","Net loss attributable to stockholders $2.0M ($0.05/sh) vs $4.7M loss in Q3 2024.","Adjusted EBITDA loss improved 96% to $0.1M from $2.4M in Q3 2024.","FY2025 revenue guidance raised to $50.5-52.5M (prev $50-52M); Surgical Aesthetics segment guided at $43-45M.","Initiated full U.S. commercial launch of AYON Body Contouring System; submitted 510(k) for power liposuction label expansion."],"consensus_eps_estimate":-0.1046,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":33680000.0,"consensus_period":"2025-Q3","consensus_source":"xbrl+finnhub","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":171683203.41025642,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":146921,"accession_number":"0001641172-25-023451","cik":719135,"company_name":"Apyx Medical Corp","ticker":"APYX","form_type":"8-K","filed_at":"2025-08-13T23:59:59+00:00","items":["5.07"],"status":"ready","headline":"Apyx Medical annual meeting: directors elected, auditor ratified, say-on-pay approved, charter amended","summary_kind":"llm","event_type":"other","confidence":"high","bullets":["All five director nominees elected with wide margins; broker non-votes ~6.8M.","RSM US LLP ratified as independent auditor for FY2025 with ~26M votes in favor.","Non-binding advisory vote on executive compensation approved (19.0M for, 0.2M against).","Frequency of advisory vote set to one year (9.2M one-year, 7.5M three-year).","Charter amendment to delete Article EIGHTH approved (19.0M for, 0.1M against)."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.2,"calibrated_materiality_score":0.15,"market_cap_usd":171683203.41025642,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":146920,"accession_number":"0001437749-25-025417","cik":719135,"company_name":"Apyx Medical Corp","ticker":"APYX","form_type":"8-K","filed_at":"2025-08-07T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Apyx Medical Q2 revenue $11.4M, net loss $3.8M; raises FY2025 revenue guidance to $50-52M","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q2 total revenue $11.4M vs $12.1M YoY; Advanced Energy flat at $9.7M, OEM down 28.5% to $1.7M.","Net loss attributable to stockholders $3.8M ($0.09/shr) vs $6.6M ($0.19/shr) YoY; adjusted EBITDA loss $2.0M vs $4.3M.","Soft launch of AYON Body Contouring System exceeding expectations; commercial launch planned September 2025.","Renuvion launched in China via partner GlamMoon; initial procedures completed with strong clinical interest.","FY2025 revenue guidance raised to $50-52M (from $47.6-49M); Advanced Energy guidance $42-44M."],"consensus_eps_estimate":-0.0952,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":20803000.0,"consensus_period":"2025-Q2","consensus_source":"xbrl+finnhub","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":171683203.41025642,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":165413,"accession_number":"0001437749-25-016259","cik":719135,"company_name":"Apyx Medical Corp","ticker":"APYX","form_type":"8-K","filed_at":"2025-05-13T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Apyx Medical receives FDA 510(k) clearance for AYON Body Contouring System","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["AYON is the first FDA-cleared all-in-one platform combining fat removal, contouring, tissue contraction, and electrosurgery.","Initial clearance covers Renuvion for lax skin, ultrasound liposuction, electrocoagulation; power liposuction submission planned later in 2025.","Commercial launch with key opinion leader surgeons in critical geographies expected in second half of 2025.","Company highlights >15 million GLP-1 drug users as a growth driver for body contouring procedures."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":171683203.41025642,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":165412,"accession_number":"0001437749-25-015231","cik":719135,"company_name":"Apyx Medical Corp","ticker":"APYX","form_type":"8-K","filed_at":"2025-05-08T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Apyx Medical Q1 revenue $9.4M (-8% YoY), Advanced Energy +6%, net loss narrows to $4.2M","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss attributable to stockholders $4.2M ($0.10/sh) vs $7.6M ($0.22/sh) prior year; adjusted EBITDA loss $2.4M vs $5.3M.","Advanced Energy revenue up 6% to $7.9M; OEM down 45% to $1.5M. Total revenue $9.4M vs $10.2M.","Reaffirmed FY2025 guidance: total revenue $47.6M-$49.0M, Advanced Energy $39.6M-$41.0M, OEM ~$8.0M.","Planned launch of AYON Body Contouring System in H2 2025 pending FDA clearance; 510(k) submitted Q1 2025.","Renuvion won 2025 NewBeauty Award for 'Best Minimally Invasive Skin Tightener'; Dolores Catania named Chief of Confidence."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":9430000.0,"consensus_period":"2025-Q1","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":171683203.41025642,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":165411,"accession_number":"0001437749-25-013413","cik":719135,"company_name":"Apyx Medical Corp","ticker":"APYX","form_type":"8-K","filed_at":"2025-04-29T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Apyx Medical announces two peer-reviewed studies on Renuvion in body contouring showing safety and efficacy","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["First prospective RCT (Barone, 76 patients) shows Renuvion improves abdominal skin laxity and satisfaction scores vs lipoabdominoplasty alone.","Second retrospective study (Vanek, 77 patients) finds no significant increase in complications with Renuvion despite longer surgical times.","CEO cites >15M patients on GLP-1 drugs as growth driver; Renuvion is only FDA-cleared device for post-liposuction skin laxity."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":171683203.41025642,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":183068,"accession_number":"0001437749-25-007383","cik":719135,"company_name":"Apyx Medical Corp","ticker":"APYX","form_type":"8-K","filed_at":"2025-03-13T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Apyx Medical Q4 2024 revenue $14.2M (down 3% YoY); net loss narrows to $4.6M; submits AYON 510(k) ahead of schedule","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q4 total revenue $14.2M (-3% YoY); Advanced Energy flat at $12.1M. Full year revenue $48.1M (-8%).","Net loss Q4 $4.6M ($0.12 per share) vs $9.6M loss in Q4 2023; adjusted EBITDA loss $2.2M vs $4.7M.","Full year 2024 net loss $23.5M ($0.66 per share) vs $18.7M; adjusted EBITDA loss $14.3M vs $13.4M.","Submitted 510(k) for AYON Body Contouring System ~90 days early; planned launch back half 2025 pending clearance.","Cost restructuring: workforce reduced ~25%, annual savings ~$4.3M. 2025 guidance: revenue $47.6-49.0M, opEx <$40M."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":171683203.41025642,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":183067,"accession_number":"0001437749-25-003036","cik":719135,"company_name":"Apyx Medical Corp","ticker":"APYX","form_type":"8-K","filed_at":"2025-02-06T23:59:59+00:00","items":["5.02","9.01"],"status":"ready","headline":"Apyx Medical names Shawn Roman COO with $305,760 base salary, bonus target ≥50%","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Shawn Roman appointed COO effective Jan 28, 2025; base salary $305,760.52.","Target annual bonus not less than 50% of base salary under board-approved plan.","Eligible for equity awards as determined by Compensation Committee.","Severance includes 12 months base pay continuation and COBRA premiums if terminated without cause or for good reason.","12-month post-employment non-compete and non-solicitation covenants apply."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.3,"calibrated_materiality_score":0.3,"market_cap_usd":171683203.41025642,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":183066,"accession_number":"0001437749-25-000927","cik":719135,"company_name":"Apyx Medical Corp","ticker":"APYX","form_type":"8-K","filed_at":"2025-01-13T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Apyx Medical prelim Q4 rev $14.1-14.3M; Advanced Energy up >25% QoQ","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Total Q4 revenue $14.1-14.3M, down ~3-4% YoY; Advanced Energy ~$12.0-12.2M (flat YoY).","Full-year 2024 revenue $48.0-48.2M, down 8% YoY; Advanced Energy down 11% to $38.5-38.7M.","OEM revenue Q4 $2.1M (-17% YoY); full-year $9.5M (+6% YoY).","New AYON Body Contouring System expected to launch H2 2025 pending FDA clearance.","CEO cites doubled U.S. generator unit sales in H2 vs H1 and GLP-1-driven demand for skin treatments."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":48102000.0,"consensus_period":"2024-FY","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":171683203.41025642,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":183065,"accession_number":"0001437749-25-000375","cik":719135,"company_name":"Apyx Medical Corp","ticker":"APYX","form_type":"8-K","filed_at":"2025-01-06T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Apyx submits 510(k) for AYON Body Contouring System; ahead of schedule","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["Submitted 510(k) premarket notification to FDA for AYON Body Contouring System.","AYON integrates infiltration, dual aspiration, ultrasound liposuction, electrocoagulation, volume enhancement, Renuvion skin tightening.","Company plans a second 510(k) later in 2025 for power-assisted liposuction.","Submission completed ~90 days earlier than originally expected, per CEO."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":171683203.41025642,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":199643,"accession_number":"0001493152-24-044154","cik":719135,"company_name":"Apyx Medical Corp","ticker":"APYX","form_type":"8-K","filed_at":"2024-11-08T23:59:59+00:00","items":["1.01","2.02","2.03","3.02","5.02","8.01","9.01"],"status":"ready","headline":"Apyx Medical Q3 revenue down 4% to $11.5M; cuts FY24 guidance; workforce –25%","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss $4.7M ($0.14/share) vs $4.6M YoY; adjusted EBITDA loss $2.4M.","Total revenue $11.5M (Advanced Energy -6% to $9.3M; OEM +3% to $2.2M).","FY24 revenue guidance cut to $46.6-47.6M from prior $50.6-52.1M; net loss expected ~$25M.","Raised ~$7M via registered direct offering of 3M shares + pre-funded warrants at $1.18/share.","Reduced U.S. workforce ~25% for ~$4.3M annual savings; three directors resigned; COO appointed."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":33880000.0,"consensus_period":"2024-Q3","consensus_source":"xbrl_only","sentiment":"negative","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":171683203.41025642,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":215660,"accession_number":"0000719135-24-000042","cik":719135,"company_name":"Apyx Medical Corp","ticker":"APYX","form_type":"8-K","filed_at":"2024-08-12T23:59:59+00:00","items":["5.07"],"status":"ready","headline":"Apyx Medical annual meeting elects all eight director nominees and ratifies auditor","summary_kind":"llm","event_type":"other","confidence":"high","bullets":["Stockholders elected all eight director nominees; votes in favor ranged from 13.2M to 14.1M.","Stavros G. Vizirgianakis received 14,111,703 votes in favor, 92,624 against.","Ratification of RSM US LLP as independent auditor for 2024 passed with 20,781,403 votes in favor.","Broker non-votes on director elections totaled 7,211,012; no broker non-votes on auditor ratification."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.05,"calibrated_materiality_score":0.05,"market_cap_usd":171683203.41025642,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":215659,"accession_number":"0000719135-24-000036","cik":719135,"company_name":"Apyx Medical Corp","ticker":"APYX","form_type":"8-K","filed_at":"2024-08-08T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Apyx Medical Q2 revenue falls 10% to $12.1M; net loss widens; updates FY2024 guidance","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Revenue $12.1M (-10% YoY); Advanced Energy -17% to $9.8M, OEM +29% to $2.4M.","Net loss $6.6M ($0.19/share) vs $1.0M loss in Q2 2023; prior year had $2.7M sale-leaseback gain.","Adjusted EBITDA loss $4.3M, up 166% from $1.6M loss in Q2 2023.","FY2024 revenue guidance narrowed to $50.6-52.1M (from $49.7-52.9M); net loss guided $23.5-24.5M (improved).","Stavros Vizirgianakis appointed Chairman effective May 7, 2024, succeeding retiring Andrew Makrides."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.41,"consensus_revenue_estimate":null,"consensus_revenue_actual":22393000.0,"consensus_period":"2024-Q2","consensus_source":"xbrl_only","sentiment":"negative","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":171683203.41025642,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":235048,"accession_number":"0000719135-24-000024","cik":719135,"company_name":"Apyx Medical Corp","ticker":"APYX","form_type":"8-K","filed_at":"2024-05-09T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Apyx Medical Q1 revenue $10.2M (-16% YoY); net loss $7.6M; Chairman retires","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Total revenue $10.2M (-16% YoY); Advanced Energy $7.5M (-23%); OEM $2.8M (+14%).","Net loss $7.6M ($0.22/share) vs $3.5M ($0.10) loss a year ago; Adjusted EBITDA loss $5.3M vs $4.0M.","Reaffirms FY2024 guidance: revenue $49.7M-$52.9M; net loss expected $24.3M-$26.5M.","Chairman Andrew Makrides retires after 42 years; Stavros Vizirgianakis elected Chairman effective May 7, 2024."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.22,"consensus_revenue_estimate":null,"consensus_revenue_actual":10244000.0,"consensus_period":"2024-Q1","consensus_source":"xbrl_only","sentiment":"negative","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":171683203.41025642,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":235047,"accession_number":"0000719135-24-000023","cik":719135,"company_name":"Apyx Medical Corp","ticker":"APYX","form_type":"8-K","filed_at":"2024-05-09T23:59:59+00:00","items":["1.01","5.02","9.01"],"status":"ready","headline":"Apyx Medical appoints Stavros Vizirgianakis as Chairman; founder Andrew Makrides retires after 40+ years","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Andrew Makrides retired as Chairman effective May 7, 2024, after serving since 1982.","Stavros Vizirgianakis appointed Chairman and director to fill vacancy; term expires at 2024 annual meeting.","Vizirgianakis is a former CEO of Misonix and current director of Xtant Medical and Medinotec.","Agreement includes standstill until 2025 annual meeting, limiting ownership to 9.9% and requiring vote with Board.","Board and Vizirgianakis will cooperate to identify an additional director within six months if he holds 5%+ shares."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":171683203.41025642,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":252873,"accession_number":"0000719135-24-000013","cik":719135,"company_name":"Apyx Medical Corp","ticker":"APYX","form_type":"8-K","filed_at":"2024-03-21T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Apyx Medical Q4 revenue up 16% to $14.7M; net loss widens to $9.6M; FY2024 guidance implies potential revenue decline","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q4 2023 Advanced Energy revenue $12.1M (+15% YoY); net loss $9.6M ($0.28/shr) vs $6.0M ($0.17) a year ago.","Full year 2023 total revenue $52.3M (+18%); net loss improved to $18.7M ($0.54/shr) from $23.2M ($0.67) in 2022.","FY2024 guidance: revenue $49.7M-$52.9M (down 5% to up 1%); net loss $24.3M-$26.5M, wider than 2023's $18.7M loss.","New $45M Perceptive credit facility closed Nov 2023; initial $37.5M funded, used to repay MidCap and $2.7M in fees.","Appointed Matthew Hill as CFO effective Dec 4, 2023."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":171683203.41025642,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":252872,"accession_number":"0000719135-24-000008","cik":719135,"company_name":"Apyx Medical Corp","ticker":"APYX","form_type":"8-K","filed_at":"2024-02-21T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Apyx Medical announces Renuvion study shows significantly fewer adverse events vs InMode RF","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Retrospective study of 450+ patients: 229 Renuvion vs 236 InMode Bipolar RF; statistically fewer adverse events (p<.0001).","Adverse events included burns, hematoma, hypertrophic scar, and seroma; Renuvion group had significantly less.","Renuvion featured in three educational sessions at AACS 40th Annual Scientific Meeting, Feb 22-24, 2024.","Dr. Michael Kluska presents the study; CEO Charlie Goodwin highlights expansion of clinical evidence supporting safety."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":171683203.41025642,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":252871,"accession_number":"0000719135-24-000005","cik":719135,"company_name":"Apyx Medical Corp","ticker":"APYX","form_type":"8-K","filed_at":"2024-01-22T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Apyx Medical publishes 483-patient study showing Renuvion safety after liposuction across multiple body areas","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Analysis of 483 patients (1,184 body areas) found no new or increased risks vs. liposuction alone.","Peer-reviewed publication in Aesthetic Surgery Journal Open Forum; data previously used for FDA 510(k) clearance in 2023.","CEO states evidence strengthens clinical portfolio for Renuvion; no alternative FDA-cleared therapy exists for the indication."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":171683203.41025642,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":252870,"accession_number":"0000719135-24-000003","cik":719135,"company_name":"Apyx Medical Corp","ticker":"APYX","form_type":"8-K","filed_at":"2024-01-08T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Apyx Medical reports preliminary Q4 rev $14.2-14.6M (+13-16% YoY); FY rev $51.9-52.3M (+17-18%)","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Total Q4 revenue $14.2-14.6M, growth 13-16% YoY; Advanced Energy $11.9-12.3M (+12-16%).","Full year total revenue $51.9-52.3M (+17-18%); Advanced Energy $43.1-43.5M (+17-18%); OEM $8.8M (+14%).","CEO says sales softer than expected due to challenging macro environment in cosmetic surgery market; slower new customer adoption.","Company plans to release full Q4 and FY 2023 results in March 2024."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.54,"consensus_revenue_estimate":null,"consensus_revenue_actual":52349000.0,"consensus_period":"2023-FY","consensus_source":"xbrl_only","sentiment":"negative","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":171683203.41025642,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":270364,"accession_number":"0000719135-23-000066","cik":719135,"company_name":"Apyx Medical Corp","ticker":"APYX","form_type":"8-K","filed_at":"2023-11-28T23:59:59+00:00","items":["5.02","7.01","9.01"],"status":"ready","headline":"Apyx Medical appoints Matthew Hill as CFO effective Dec 4, 2023","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Matthew Hill appointed CFO, effective Dec 4, 2023, succeeding Tara Semb who departed Nov 9.","Hill brings 30+ years experience, previously CFO of PDS Biotech, Strata Skin Sciences, and other healthcare firms.","Employment terms: $425K base salary, $50K sign-on bonus, target bonus ≥50% of base, stock option for 150K shares.","Hill will also serve as Principal Financial Officer and Principal Accounting Officer."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":171683203.41025642,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":270363,"accession_number":"0000719135-23-000063","cik":719135,"company_name":"Apyx Medical Corp","ticker":"APYX","form_type":"8-K","filed_at":"2023-11-16T23:59:59+00:00","items":["5.02"],"status":"ready","headline":"CFO Tara Semb to depart Apyx Medical; successor identified but not named","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["CFO Tara Semb leaving to pursue other opportunities, effective upon appointment of successor.","Departure not due to any disagreement with company on operations, policies, or financial reporting.","Board initiated formal search; successor has been identified and will be formally appointed.","Ms. Semb will remain as CFO until successor is in place.","Date of report: November 9, 2023; signed November 16, 2023 by CEO Charles D. Goodwin, II."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":171683203.41025642,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":270362,"accession_number":"0001493152-23-040084","cik":719135,"company_name":"Apyx Medical Corp","ticker":"APYX","form_type":"8-K","filed_at":"2023-11-09T23:59:59+00:00","items":["1.01","1.02","2.03","9.01"],"status":"ready","headline":"Apyx Medical enters up to $45M debt facility with Perceptive, replaces MidCap loan","summary_kind":"llm","event_type":"debt","confidence":"high","bullets":["Initial $37.5M funded Nov 8; up to $7.5M delayed draw available through Dec 31, 2024 subject to conditions.","Proceeds used to repay ~$11M of MidCap debt (incl. ~$1M prepayment penalties) and ~$2.5M transaction fees.","Interest: 1-month SOFR + 7% (5% floor); 48-month interest-only period; matures Nov 8, 2028.","Warrants issued to Perceptive: 1.25M shares at $2.43/share; additional 0.25M upon delayed draw.","Financial covenants: minimum trailing 12-month Advanced Energy revenue targets (2024: $41.6M, 2025: $57.0M); $3M min cash."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":171683203.41025642,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":270361,"accession_number":"0000719135-23-000054","cik":719135,"company_name":"Apyx Medical Corp","ticker":"APYX","form_type":"8-K","filed_at":"2023-11-09T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Apyx Medical Q3 revenue up 31% to $12.0M; cuts FY2023 revenue guidance sharply","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q3 Advanced Energy revenue $9.8M (+39%); total revenue $12.0M (+31%); net loss $4.6M improved 20% YoY.","Cuts FY2023 revenue guidance to $53-54M from $59-62M; Advanced Energy now $44.5-45.5M from $51-54M.","Secured $45M credit facility with Perceptive; initial $37.5M funded; used to repay MidCap debt.","CFO Tara Semb to leave; successor identified but not named; departure not due to disagreement."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.26,"consensus_revenue_estimate":null,"consensus_revenue_actual":37687000.0,"consensus_period":"2023-Q3","consensus_source":"xbrl_only","sentiment":"negative","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":171683203.41025642,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":287323,"accession_number":"0000719135-23-000049","cik":719135,"company_name":"Apyx Medical Corp","ticker":"APYX","form_type":"8-K","filed_at":"2023-08-16T23:59:59+00:00","items":["5.07"],"status":"ready","headline":"Apyx Medical annual meeting elects 8 directors, ratifies auditor, approves 2023 incentive plan","summary_kind":"llm","event_type":"other","confidence":"high","bullets":["All 8 director nominees elected, including Andrew Makrides (18.7M for, 224K against) and Charles Goodwin (19.0M for, 21K against).","Ratification of RSM US LLP as auditor: 24,542,917 for, 26,534 against, 53,343 abstentions.","Approval of 2023 Share Incentive Plan: 15,970,459 for, 1,405,162 against, 1,613,512 abstentions.","Meeting held August 10, 2023; all proposals passed as recommended by the Board."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.15,"calibrated_materiality_score":0.15,"market_cap_usd":171683203.41025642,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":287322,"accession_number":"0000719135-23-000045","cik":719135,"company_name":"Apyx Medical Corp","ticker":"APYX","form_type":"8-K","filed_at":"2023-08-10T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Apyx Medical Q2 revenue up 32% to $13.6M, net loss narrows 82% to $1.0M, reaffirms FY2023 guide","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Advanced Energy revenue rose 40% YoY to $11.7M; OEM revenue fell 4% to $1.8M.","Net loss improved to $1.0M ($0.03 loss per share) from $5.4M in Q2 2022.","Adjusted EBITDA loss decreased 52% to $1.6M; gross margin expanded to 68.4%.","FY2023 outlook reaffirmed: total revenue $59-62M, Advanced Energy $51-54M, net loss ~$10.5M.","Completed sale-leaseback of Clearwater facility, netting ~$6.6M; received two FDA 510(k) clearances in Q2."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.13,"consensus_revenue_estimate":null,"consensus_revenue_actual":25711000.0,"consensus_period":"2023-Q2","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":171683203.41025642,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":307445,"accession_number":"0000719135-23-000025","cik":719135,"company_name":"Apyx Medical Corp","ticker":"APYX","form_type":"8-K","filed_at":"2023-05-11T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Apyx Medical Q1 revenue $12.1M (-3% YoY); raises FY2023 guidance; FDA updates Safety Communication","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Total revenue $12.1M (-3% YoY); Advanced Energy $9.7M (-10%); OEM $2.5M (+46%).","Net loss $3.5M ($0.10/share) improved from $5.9M loss in Q1 2022; Adjusted EBITDA loss $4.0M.","Raises FY2023 total revenue guidance to $59-62M (prior $58-61M); Advanced Energy $51-54M; net loss expected ~$10.5M.","FDA updated Safety Communication on May 10 clearing Renuvion APR handpiece for subcutaneous soft tissue coagulation post-liposuction.","Closed sale-leaseback of Clearwater facility for $6.6M net cash; secured $35M credit facility with MidCap."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.1,"consensus_revenue_estimate":null,"consensus_revenue_actual":12142000.0,"consensus_period":"2023-Q1","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":171683203.41025642,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":307444,"accession_number":"0000719135-23-000022","cik":719135,"company_name":"Apyx Medical Corp","ticker":"APYX","form_type":"8-K","filed_at":"2023-04-18T23:59:59+00:00","items":["1.01","9.01"],"status":"ready","headline":"Apyx Medical extends property sale inspection period to May 4, 2023, closing to May 8","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Amendment extends Inspection Period for Clearwater facility sale to 5:00 p.m. ET on May 4, 2023.","Closing deadline extended to on or before May 8, 2023; purchase price remains $7.65 million.","All other terms of the original Purchase and Sale Agreement unchanged.","Original agreement signed March 14, 2023; buyer VK Acquisitions VI, LLC."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.25,"calibrated_materiality_score":0.25,"market_cap_usd":171683203.41025642,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":326460,"accession_number":"0000719135-23-000015","cik":719135,"company_name":"Apyx Medical Corp","ticker":"APYX","form_type":"8-K","filed_at":"2023-03-16T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Apyx Medical Q4 2022 revenue down 25% to $12.6M; net loss $6.0M; guides 2023 rev $58-61M","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q4 total revenue $12.6M (-25% YoY); Advanced Energy segment $10.5M (-30% YoY); OEM $2.1M (+15% YoY).","FY2022 net loss $23.2M ($0.67/share) vs $15.2M in 2021; adjusted EBITDA loss $15.4M vs $8.8M.","Introduces FY2023 guidance: total revenue $58-61M (30-37% growth); net loss ~$14M vs $23.2M in 2022.","Post-quarter: FDA 510(k) clearance for Renuvion APR Handpiece (Feb 27); $35M credit facility with MidCap Financial.","CEO cites FDA Safety Communication disruption; expects >35% Advanced Energy growth in 2023."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":171683203.41025642,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":326459,"accession_number":"0000719135-23-000012","cik":719135,"company_name":"Apyx Medical Corp","ticker":"APYX","form_type":"8-K","filed_at":"2023-03-15T23:59:59+00:00","items":["1.01","9.01"],"status":"ready","headline":"Apyx Medical sells headquarters for $7.65M in sale-leaseback; expects $6.7M net proceeds","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Sale price $7,650,000 for Clearwater, FL facility; net proceeds estimated at ~$6.7M after taxes and fees.","Leaseback for 10-year initial term at $619,500 annual rent, escalating 4% per year; triple-net lease.","Proceeds will be used to strengthen balance sheet and provide working capital.","Purchaser paid $400,000 earnest money; due diligence period of 30 days from March 14, 2023."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":171683203.41025642,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":326458,"accession_number":"0000719135-23-000009","cik":719135,"company_name":"Apyx Medical Corp","ticker":"APYX","form_type":"8-K","filed_at":"2023-02-24T23:59:59+00:00","items":["1.01","2.03","9.01"],"status":"ready","headline":"Apyx Medical enters $35M credit facility with MidCap Financial; initial $10M funded","summary_kind":"llm","event_type":"debt","confidence":"high","bullets":["Up to $25M senior secured term loan (initial $10M funded) plus $10M revolver; matures Feb 1, 2028.","Term loan bears SOFR + 7.35% (floor 2.5%); revolver SOFR + 4.0%; 24-month interest-only period.","Warrants issued to MidCap to purchase 250,000 shares at $3.40 per share.","Covenants include minimum Advanced Energy revenue targets of $49M (2023), $60M (2024), $70M (2025) and $10M cash balance.","Net proceeds of ~$8M at close plus expected $7.5M+ cash tax refunds to fund growth initiatives."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":171683203.41025642,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":326457,"accession_number":"0000719135-23-000002","cik":719135,"company_name":"Apyx Medical Corp","ticker":"APYX","form_type":"8-K","filed_at":"2023-01-10T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Apyx Medical reports preliminary Q4 revenue $12.1-12.5M (-26-28% YoY); full year $44-44.4M (-8-9%)","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Advanced Energy rev Q4 $10.1-10.5M (-30-33% YoY); OEM rev $2.0M (+12% YoY).","Full year Advanced Energy $36.4-36.8M (-14-15%); OEM $7.6M (+37%).","CEO cites continued disruption from FDA Medical Device Safety Communication.","Expects 2023 Advanced Energy sales growth >35% YoY; plans to submit 510(k) for new indication by Jan 2023.","Implementing expense cuts to improve cash flow; evaluating options for liquidity enhancement."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.67,"consensus_revenue_estimate":null,"consensus_revenue_actual":44510000.0,"consensus_period":"2022-FY","consensus_source":"xbrl_only","sentiment":"negative","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":171683203.41025642,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":344182,"accession_number":"0000719135-22-000088","cik":719135,"company_name":"Apyx Medical Corp","ticker":"APYX","form_type":"8-K","filed_at":"2022-11-10T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Apyx Medical Q3 revenue down 23% YoY; cuts full-year 2022 guidance","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Total revenue $9.1M (-23% YoY); Advanced Energy revenue $7.1M (-31% YoY).","Net loss $5.8M ($0.17/share) vs $4.2M loss in Q3 2021; Adjusted EBITDA loss $3.9M.","Full-year 2022 revenue guidance cut to $44.8M-$47.9M from prior $51.0M-$56.4M.","Company cites continued disruption from March FDA Safety Communication as primary headwind.","OEM revenue grew 34% to $2.0M, partially offsetting Advanced Energy decline."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.5,"consensus_revenue_estimate":null,"consensus_revenue_actual":31899000.0,"consensus_period":"2022-Q3","consensus_source":"xbrl_only","sentiment":"negative","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":171683203.41025642,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":360671,"accession_number":"0000719135-22-000080","cik":719135,"company_name":"Apyx Medical Corp","ticker":"APYX","form_type":"8-K","filed_at":"2022-08-17T23:59:59+00:00","items":["5.07"],"status":"ready","headline":"Apyx Medical announces annual meeting results; all director nominees elected, auditor ratified, say-on-pay approved","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["All eight director nominees elected; votes ranged from 15,768,279 for Minnie Baylor-Henry to 15,909,798 for Wendy Levine.","RSM US LLP ratified as independent auditor for FY2022 with 21,352,026 votes for, 83,026 against.","Non-binding advisory resolution on executive compensation approved with 15,568,856 for, 366,319 against."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.2,"calibrated_materiality_score":0.15,"market_cap_usd":171683203.41025642,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":360670,"accession_number":"0000719135-22-000062","cik":719135,"company_name":"Apyx Medical Corp","ticker":"APYX","form_type":"8-K","filed_at":"2022-08-11T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Apyx Medical Q2 revenue down 8% YoY; narrows 2022 guidance","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Total revenue $10.3M (-8% YoY); Advanced Energy revenue $8.4M (-16% YoY), OEM $1.9M (+55%).","Net loss $5.4M ($0.16 loss per share) vs $4.0M loss in Q2 2021; Adj. EBITDA loss $3.4M vs $2.4M.","Full-year revenue guidance narrowed to $51-56.4M (prev $52.5-59M); net loss guidance widened to $20.1-16.6M.","FDA granted 510(k) clearance for Renuvion Dermal Handpiece (wrinkles) and APR Handpiece (lax skin).","International Advanced Energy generator and handpiece sales fell >45% and >30% YoY respectively."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.33,"consensus_revenue_estimate":null,"consensus_revenue_actual":22785000.0,"consensus_period":"2022-Q2","consensus_source":"xbrl_only","sentiment":"negative","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":171683203.41025642,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":360669,"accession_number":"0000719135-22-000058","cik":719135,"company_name":"Apyx Medical Corp","ticker":"APYX","form_type":"8-K","filed_at":"2022-07-18T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Apyx Medical receives FDA 510(k) clearance for Renuvion to treat loose skin on neck and chin","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["FDA clearance for Renuvion APR Handpiece for subcutaneous procedures to improve appearance of lax skin in neck and submental region.","Renuvion is now the only FDA-cleared device for improving loose skin on neck and chin; targets ~200,000 annual US neck contouring procedures.","Limited launch expected by end of Q3 2022, full commercialization by end of 2022.","Clearance supported by safety and efficacy data from a U.S. IDE clinical study; results announced July 8, 2022.","This is the second regulatory clearance for a specific clinical indication in less than two months."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":171683203.41025642,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":379793,"accession_number":"0000719135-22-000044","cik":719135,"company_name":"Apyx Medical Corp","ticker":"APYX","form_type":"8-K","filed_at":"2022-06-13T23:59:59+00:00","items":["8.01"],"status":"ready","headline":"Apyx Medical named in securities class action over off-label product statements","summary_kind":"llm","event_type":"litigation","confidence":"high","bullets":["Plaintiff William Hattaway filed securities class action in Middle District of Florida on June 6, 2022.","Defendants: Apyx Medical, CEO Charles Goodwin, CFO Tara Semb; claims under Sections 10(b) and 20(a).","Allegations focus on public statements regarding off-label use of Advanced Energy products; class period May 12, 2021 - Mar 11, 2022.","Complaint seeks unspecified damages; company states allegations are without merit and will defend vigorously.","The complaint has not yet been served on the company."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":171683203.41025642,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":379792,"accession_number":"0000719135-22-000040","cik":719135,"company_name":"Apyx Medical Corp","ticker":"APYX","form_type":"8-K","filed_at":"2022-05-26T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Apyx Medical gets FDA 510(k) clearance for Renuvion dermal resurfacing handpiece","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["Clearance for treatment of moderate to severe wrinkles, limited to Fitzpatrick skin types I–III.","Addressable market of ~200,000 wrinkle reduction procedures annually in the U.S.","Renuvion Dermal Handpiece indicated for specific dermal resurfacing procedures.","Limited launch planned for Q3 2022; full commercialization targeted by end of 2022.","CEO calls it 'one of the most important achievements' in the U.S. cosmetic surgery strategy."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":171683203.41025642,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":379791,"accession_number":"0000719135-22-000030","cik":719135,"company_name":"Apyx Medical Corp","ticker":"APYX","form_type":"8-K","filed_at":"2022-05-12T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Apyx Medical Q1 revenue up 45% to $12.5M, net loss widens, guidance narrowed","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Revenue $12.5M (+45% YoY); Advanced Energy $10.8M (+41%), OEM $1.7M (+72%).","Net loss attributable to stockholders $5.9M ($0.17/share) vs $4.9M ($0.14) prior year.","Adjusted EBITDA loss $4.0M vs $3.4M; operating expenses rose 33% to $14.1M.","FY2022 revenue guidance narrowed to $52.5-59.0M (prior $50-63M); Advanced Energy $46-52M (prior $43.5-56M).","FDA Safety Communication in March impacted U.S. new customer adoption; 510(k) submissions for dermal/laxity pending."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.17,"consensus_revenue_estimate":null,"consensus_revenue_actual":12493000.0,"consensus_period":"2022-Q1","consensus_source":"xbrl_only","sentiment":"negative","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":171683203.41025642,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null}],"next_cursor":"2022-05-12T23:59:59+00:00|379791"}